Cancer Drugs - Statistics

General Stats

Answer Stats

Hint	Answer	% Correct
Targets HER2+ to prevent homodimerisation	trastuzumab	63%
VEGF inhibitor, restricting angiogenesis	bevacizumab	50%
CDK inhibitor for HER2- and HR+ breast cancer	palbociclib	38%
PD-L1R inhibitor for triple - breast cancer	pembrolizumab	38%
mTOR inhibitor for renal and pancreatic cancers	everolimus	25%
CDK inhibitor for HER2- and HR+ breast cancer	ribociclib	25%
Locks KRAS G12C in inactive form for NSCL cancer	adagrasib	13%
ADC for HER2+ breast cancer	ado-trastuzumab emtansine	13%
Tri-specific for EpCAM+ cancers	catumaxomab	13%
EGFR and HER1 inhibitor for bowel, neck, and head cancers	cetuximab	13%
PD-L1 inhibitor for non-small cell lung cancer (NSCL)	durvalumab	13%
PI3K inhibitor for blood cancers	idelalisib	13%
Targets HER2+ to prevent heterodimerisation with HER3	pertuzumab	13%
Recruit E3 ligase to KRAS for degradation by ubiquitin	PROTACs	13%
G12C mutation inhibitor for NSCL cancer	sotorasib	13%
PI3K inhibitor for breast cancers	alpelisib	0%
BiTE for CD19+ ALL cancers	blinatumomab	0%
Akt inhibitor for breast cancer	capivaseritib	0%
ADC for acute lymphoblastic leukaemia (ALL)	inotuzumab ozogamicin	0%
Dual PI3K and mTOR inhibitor	paxalisib	0%
BiTE for Muc17+ cancers	vepsitamab	0%

Score Distribution

Percent of People with Each Score

Percentile by Number Answered

Your Score History

You have not taken this quiz